ArticleJournal of cardiothoracic surgery2026
The potential clinical value of combining serum miR-769-5p with lung ultrasound for the diagnosis of acute lung injury.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute lung injury (ALI) represents a life-threatening condition triggered by diverse etiological factors. The expression and function of miR-769-5p within the context of ALI remain poorly characterized. PURPOSE: This study aims to examine the expression levels of miR-769-5p in the serum of ALI patients and assess its synergistic diagnostic potential when combined with the lung ultrasound (LUS) score for ALI.
methodsSerum miR-769-5p expression levels were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic accuracy of miR-769-5p and the LUS score for ALI was evaluated via receiver operating characteristic (ROC) curve analysis. Binary logistic regression was used to analyze their impact on ALI. Serum nuclear factor kappa B (NF-κB) and reactive oxygen species (ROS) levels were measured by enzyme-linked immunosorbent assay (ELISA). Pearson correlation assessed relationships between miR-769-5p and NF-κB, ROS, and LUS score. In lipopolysaccharide (LPS)-A549 cells, RT-qPCR and flow cytometry evaluated how miR-769-5p modulated NF-κB, ROS, and apoptosis.
resultsALI patients exhibited significantly decreased serum miR-769-5p expression. Combining miR-769-5p with the LUS score enhanced diagnostic accuracy, with both correlating significantly with ALI risk. Serum NF-κB and ROS levels were elevated in ALI and inversely correlated with miR-769-5p. In LPS-A549 cells, miR-769-5p overexpression suppressed LPS-induced NF-κB activation, ROS generation, and cellular apoptosis.
conclusionsThe combined application of miR-769-5p and the LUS score demonstrated enhanced diagnostic efficacy. Furthermore, miR-769-5p overexpression effectively attenuated NF-κB activation, ROS production, and cellular apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.